Glenmark Pharmaceuticals Limited has informed the Exchange that Board of Directors at its meeting held on September 26, 2025, declared Interim Dividend of 2.5 per equity share.
GLENMARK · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.7 pts less than Nifty Midcap 150 and 0.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Glenmark Pharmaceuticals' Board, at its meeting on September 26, 2025, approved an Interim Dividend of ₹2.50 per equity share on a face value of ₹1 per share for FY 2025-26. The total dividend payout amounts to approximately ₹705.50 millions. The record date for eligibility has been set as Friday, October 3, 2025, and the dividend will be paid within 30 days of declaration. The Board also approved reconstitution of three committees — Stakeholders Relationship, Risk Management, and ESG — effective October 1, 2025.
Shareholders holding Glenmark shares as of the record date (October 3, 2025) will receive ₹2.50 per share, offering a modest cash inflow. Given the company's typical share price levels, this translates to a low single-digit yield, likely a minor positive sentiment signal rather than a major catalyst for the stock.